The development of BCR:: ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved the
prognosis of patients with chronic myeloid leukemia (CML). Although there are some …

Abstract Each year, the American Cancer Society estimates the numbers of new cancer
cases and deaths in the United States and compiles the most recent data on population …

In this provocative commentary, we consider several questions posed by the late chronic
myeloid leukaemia (CML) expert Prof. Michele Baccarani, which he challenged us to …

Leukemias are cancers of the blood-forming system, representing a significant challenge in
medical science. The development of leukemia cells involves substantial disturbances …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm initiated by the presence
of the fusion gene BCR:: ABL1. The development of tyrosine kinase inhibitors (TKIs) highly …

Background The relationship between ferroptosis and the progression and treatment of
hematological tumors has been extensively studied, although its precise association with …

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by
accumulation of immature cells in bone marrow and peripheral blood. Although successful …

Molecular recurrence (MRec) occurs in about half of all patients with chronic myeloid
leukaemia (CML) who discontinue tyrosine kinase inhibitors (TKI) in sustained deep …

Introduction: Calcium flux is the master second messenger that influences the proliferation–
apoptosis balance. The ability of calcium flux alterations to reduce cell growth makes ion …

Chronic myeloid leukemia (CML) is characterized by the fusion protein BCR:: ABL1, a
constitutively active tyrosine kinase. The frontline treatment, represented by tyrosine kinase …